Dentritic heparin nano-material modified biological type artificial blood vessel

Abstract

The invention discloses a dentritic heparin nano-material and a modified biological type artificial blood vessel. The dentritic heparin nano-material provided by the invention has a terminal branch unit shown in formula I, and is obtained by a reaction between polyamidoaminedendrimers using hydrazide group as a terminal group and heparin, wherein the inner core of the polyamidoaminedendrimers is cystamine, and the dentritic frame of the polyamidoamine dendrimers is hydrazide modified polyamidoamine including -0.5, 0.5, 1.5, 2.5, 3.5, 4.5, 5.5, 6.5 and 7.5; and the connection between the heparin and polyamidoamine is a glycosidic bond formed a reaction between the hydrazide on the surface of the polyamidoamine and the heparin reducing terminal. The disulfide bond in the dentritic heparin nano-material is cut through a reducing agent to obtain a sulfydryl site which can react with an intravascular stent material; and the surface in a blood vessel can be activated through a coupling agent of a two-way functional group, and the heparin with a branch structure can be fixed on the inner surface of the blood vessel material through chemical bond covalence, so that a composite artificial blood vessel with an anticoagulation effect can be obtained.

Description

technical field [0001] The invention relates to a bioartificial blood vessel modified by a dendritic heparin nanometer material. Background technique [0002] Artificial blood vessels are mainly used for replacement repair of human tissue blood vessels. At present, large-caliber artificial blood vessels based on artificial materials (such as polyester and polytetrafluoroethylene) have been used clinically, while small-caliber artificial blood vessels (diameter less than 6mm) have not been clinically produced. The main reasons are the slow blood flow and low blood pressure of small-caliber vessels, which are prone to acute thrombosis, anastomotic intimal hyperplasia, aneurysm, infection and atherosclerosis. In current clinical treatment, the substitutes for small-caliber vascular grafts are mostly autologous blood vessels (such as vascular tissue from the great saphenous vein). However, many patients may not be able to provide transplantable blood vessels due to other vascul...

AI Technical Summary

Problems solved by technology

However, despite the natural structure and composition of acellular matrices, their surface properties may still not meet the needs of biomaterial compatibility and tissue regeneration.

The small-diameter blood vessels based on acellular matrix (that is, biological blood vessels) currently have the following problems: thrombus generally forms within half a year; endothelialization of the inner surface of blood vessels and regeneration and remodeling of implantable materials by vascular smooth muscle cells are difficult to occur

[0013] 2. The inner surface of blood vessels can be modified by using the functional groups of natural materials, but the current method generally needs to directly react with functional groups such as heparin carboxyl groups and material surface amino groups. This reaction method is difficult to have a clear heparin modification site, and the activity of heparin is difficult. ensure;

[0014] 3. Due to the limited number of modifiable groups on the surface of vascular materials, it is difficult to control the amount of heparin modification

Images